rtpcr
sensit
assay
diagnosi
influenza
due
enhanc
rapid
sensit
compar
classic
method
heminest
rtpcr
develop
target
np
gene
influenza
ns
gene
influenza
b
base
previou
singl
round
rtpcr
method
new
method
compar
previou
techniqu
analyt
sensit
specif
appli
clinic
sampl
lower
upper
respiratori
tract
analyt
sensit
heminest
rtpcr
influenza
time
influenza
b
higher
previou
method
high
specif
new
heminest
rtpcr
assay
observ
use
whole
respiratori
virus
appli
lower
respiratori
tract
specimen
new
method
show
increas
rate
posit
compar
previou
techniqu
versu
influenza
versu
influenza
b
screen
upper
respiratori
tract
sampl
collect
season
outbreak
indic
posit
influenza
b
respect
result
confirm
sequenc
analysi
apart
influenza
b
influenza
subtyp
associ
season
outbreak
detect
infect
due
b
influenza
viru
caus
substanti
annual
morbid
hospit
mortal
worldwid
especi
case
infant
elderli
immunocompromis
patient
lewi
nicholson
et
al
howev
influenza
viru
infect
often
underdiagnos
addit
influenza
virus
cocircul
respiratori
pathogen
also
caus
influenzalik
ill
henc
import
differenti
influenza
respiratori
diseas
nicholson
et
al
addit
opportun
administ
earli
antivir
treatment
avail
rapid
diagnosi
viral
respiratori
infect
associ
judici
antibiot
use
prevent
nosocomi
spread
reduc
length
hospit
stay
ultim
reduc
cost
barenfang
et
al
cox
subbarao
woo
et
al
reason
avail
sensit
tool
diagnosi
influenza
viru
utmost
import
order
optim
clinic
manag
reduc
risk
spread
contact
exclud
influenzalik
pathogen
well
surveil
influenza
virus
commun
turn
import
provid
inform
concern
circul
subtyp
includ
potenti
avian
influenza
virus
classic
diagnosi
influenza
viru
infect
base
viral
isol
tissu
cultur
subsequ
hemagglutin
neuraminidas
subtyp
serolog
method
mcintosh
howev
method
cumbersom
time
consum
requir
special
personnel
church
et
al
sintchenko
et
al
show
good
specif
accept
sensit
rtpcr
wright
et
al
multiplex
rtpcr
poddar
realtim
pcr
hindiyeh
et
al
smith
et
al
present
consid
sensit
assay
detect
influenza
virus
studi
rtpcr
method
establish
origin
wright
et
al
modifi
design
intern
primer
set
establish
heminest
rtpcr
new
heminest
rtpcr
evalu
analyt
sensit
specif
abil
detect
concomitantli
distinguish
influenza
virus
b
respiratori
specimen
refer
strain
aptchalm
use
posit
control
set
plasmid
contain
insert
region
target
rtpcr
virus
cultur
mdck
cell
viru
stock
aliquot
store
c
use
total
lower
respiratori
tract
sampl
sputum
endotrach
aspir
bronchoalveolar
lavag
collect
hospit
patient
consequ
sent
microbiolog
laboratori
three
hospit
itali
march
may
addit
nasopharyng
swab
patient
influenzalik
ill
collect
laboratori
survey
season
outbreak
februaryapril
lower
respiratori
tract
sampl
dilut
sputasol
solut
oxoid
ltd
basingstok
england
underw
dnarna
extract
use
boom
method
boom
et
al
nuclisen
reagent
durham
nc
usa
unrel
dna
dna
rna
phage
genom
control
ad
sampl
extract
target
control
sequenc
amplifi
parallel
pcr
rtpcr
control
presenc
inhibitor
sampl
matrix
revers
transcript
rna
carri
random
primer
use
revers
transcriptas
kit
invitrogen
milan
itali
accord
manufactur
instruct
cdna
obtain
amplifi
pcr
use
geneamp
dna
amplif
reagent
kit
appli
biosystem
roch
branchburg
new
jersey
usa
detect
influenza
b
virus
singl
round
rtpcr
target
np
ns
gene
influenza
b
respect
new
heminest
rtpcr
method
use
posit
neg
control
contain
viral
rna
extract
nucleasefre
water
respect
includ
rtpcr
tube
origin
singl
round
rtpcr
describ
wright
et
al
primer
influenza
influenza
b
amplicon
size
bp
bp
influenza
b
respect
method
use
refer
valid
new
method
new
method
base
modif
previou
techniqu
base
two
round
pcr
heminest
format
first
round
set
primer
use
amplif
condit
modifi
slightli
respect
origin
method
specif
l
cdna
ad
pcr
tube
first
round
amplif
pcr
condit
includ
specif
primer
l
final
reaction
volum
contain
u
taq
gold
dna
polymeras
dntp
mm
trishcl
ph
mm
potassium
chlorid
mm
magnesium
chlorid
amplif
condit
follow
denatur
min
c
cycl
min
c
min
c
min
c
final
cycl
elong
step
min
includ
end
second
round
two
intern
sens
primer
design
posit
genbank
access
number
influenza
viru
posit
genbank
access
number
influenza
b
viru
l
first
amplif
tube
use
reaction
mixtur
first
round
amplif
condit
follow
denatur
min
c
cycl
min
c
min
c
min
c
final
cycl
elong
step
min
includ
end
amplifi
product
l
analyz
agaros
gel
electrophoresi
visual
uv
fluoresc
stain
ethidium
bromid
amplicon
size
slightli
shorter
first
round
reaction
bp
bp
respect
fig
new
method
test
first
rna
extract
viru
stock
appli
serial
dilut
plasmid
contain
insert
target
region
influenza
b
virus
assess
sensit
modifi
amplif
protocol
pcr
product
obtain
use
clone
construct
plasmid
specif
amplifi
product
purifi
qiaquick
pcr
purif
kit
qiagen
gmbh
germani
ligat
pcr
vector
contain
topo
ta
clone
kit
invitrogen
life
technolog
carlsbad
ca
usa
transform
compet
escherichia
coli
cell
use
one
shot
system
invitrogen
life
technolog
carlsbad
ca
usa
plasmid
dna
extract
use
qiaprep
miniprep
kit
qiagen
gmbh
germani
transform
plasmid
extract
known
copi
number
obtain
recombin
plasmid
use
perform
limit
dilut
pcr
amplif
use
replic
tube
dilut
sensit
reaction
calcul
epa
probit
analysi
program
version
specif
new
heminest
rtpcr
assay
establish
use
panel
plasmid
contain
target
region
follow
respiratori
virus
human
metapneumoviru
hmpv
adenoviru
adv
parainfluenzaviru
piv
respiratori
syncyti
viru
rsv
human
rhinoviru
hrv
well
human
coronaviru
hcov
addit
prepar
contain
whole
virus
hmpv
rsv
hrv
test
specif
new
method
clinic
sampl
obtain
sequenc
amplicon
heminest
rtpcr
independ
confirmationsubtyp
base
sequenc
differ
target
gene
ha
n
sequenc
perform
autom
abi
prism
instrument
use
bigdy
termin
cycl
sequenc
kit
appli
biosystem
warrington
uk
serial
dilut
two
plasmid
contain
target
region
virus
test
replic
assay
establish
analyt
sensit
shown
fig
amplicon
detect
higher
dilut
influenza
b
respect
new
method
compar
refer
method
sensit
establish
probit
analysi
ie
concentr
target
sequenc
result
posit
case
result
copi
influenza
b
refer
rtpcr
copi
heminest
rtpcr
respect
specif
none
plasmid
whole
viru
prepar
result
posit
interf
influenza
bspecif
rtpcr
assay
result
reproduc
three
pcr
run
total
lower
respiratori
sampl
test
two
method
result
shown
tabl
show
signific
increas
rate
posit
influenza
b
new
method
compar
refer
method
none
sampl
result
posit
refer
method
test
neg
heminest
method
distribut
case
detect
heminest
rtpcr
expect
basi
season
influenza
activ
correspond
period
peak
januaryfebruari
fig
addit
shown
tabl
sampl
also
posit
respiratori
virus
new
method
appli
nasopharyng
swab
patient
influenzalik
ill
collect
season
outbreak
result
posit
influenza
posit
influenza
b
also
case
relev
proport
sampl
n
posit
respiratori
virus
confirm
specif
heminest
rtpcr
influenza
influenza
b
sequenc
indic
case
expect
sequenc
obtain
eighteen
posit
sampl
influenza
b
influenza
subject
amplificationsequenc
differ
target
gene
ie
ha
n
influenza
ha
influenza
b
independ
confirmationsubtyp
approach
confirm
presenc
influenza
b
sampl
addit
ha
n
sequenc
data
sampl
indic
n
n
subtyp
repres
clinic
seri
sampl
independ
confirm
influenza
base
gene
sequenc
data
influenza
viru
confirm
sequencingsubtyp
also
obtain
sampl
contain
respiratori
virus
hcov
hrv
indic
new
method
interfer
influenza
viru
detect
due
concomit
presenc
virus
analyt
sensit
new
molecular
method
establish
detect
influenza
b
base
heminest
rtpcr
result
indic
analyt
sensit
improv
approxim
time
influenza
time
influenza
b
comparison
refer
method
new
method
specif
result
new
method
detect
virus
significantli
higher
proport
clinic
sampl
lower
sputum
endotrach
aspir
bronchoalveolar
lavag
respiratori
tract
compar
singl
round
rtpcr
addit
screen
nasopharyng
swab
collect
winter
season
outbreak
influenza
new
method
indic
posit
influenza
b
respect
high
specif
new
method
may
deduc
fact
posit
sampl
undergo
sequenc
analysi
confirm
presenc
influenza
b
virus
molecular
subtyp
indic
new
method
detect
influenza
subtyp
involv
season
outbreak
furthermor
lack
interfer
deduc
fact
substanti
proport
specimen
posit
heminest
influenza
rtpcr
also
posit
least
one
addit
respiratori
viru
sequenc
analysi
confirm
presenc
influenza
multipli
infect
sampl
studi
show
heminest
rtpcr
influenza
b
virus
develop
sensit
specif
suggest
improv
diagnost
perform
clinic
set
howev
present
method
base
multipl
step
pcr
may
disadvantag
increas
complex
time
reagent
use
cost
possibl
contamin
disadvantag
may
overcom
use
carri
prevent
system
uracilnglycosylas
ung
one
step
rtpcr
kit
method
add
complex
oper
step
cdna
prepar
suitabl
respiratori
sampl
often
undergo
multipl
amplif
reaction
respiratori
viru
panel
recent
approach
base
real
time
pcr
may
help
solv
issu
howev
consid
end
point
pcr
still
use
mani
diagnost
laboratori
therefor
method
describ
paper
valid
option
detect
influenza
virus
upper
lower
respiratori
tract
clinic
sampl
substanti
contribut
establish
etiolog
lower
respiratori
tract
diseas
influenzalik
ill
studi
preval
respiratori
virus
studi
support
part
grant
italian
ministri
health
fondi
ricerca
corrent
ricerca
finalizzata
fondi
per
la
creazion
di
un
polo
centralizzato
per
la
crioconservazion
inmi
l
spallanzani
neither
fund
sourc
influenc
design
conduct
report
studi
carla
nisii
anna
prygodzicz
grate
acknowledg
assist
write
manuscript
